Filtered By:
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 93 results found since Jan 2013.
Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease
AbstractAnti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy (IIM). In comparison to interstitial lung disease (ILD) in polymyositis and dermatomyositis (PM/DM), ILD in ASS is more frequent, has a more aggressive phenotype, a greater involvement of the lungs, and a more rapid onset of pulmonary symptoms. Continuous declines in predicted forced vital capacity (FVC) and dyspnea were the main features of patients who developed end-stage ILD. The severity of ASS at diagnosis dictates when and which immunosuppressant will be started. There is an experience for the usage of RTX in the first, second, and subseque...
Source: Rheumatology International - April 25, 2023 Category: Rheumatology Source Type: research
Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
In conclusion, iTTP may be a rare complication of IIM that clinicians should consider in cases of marked thrombocytopenia. Further work-up of this finding should include a peripheral blood smear (schistocyte count) andADAMTS13 activity. The concomitant manifestation of these autoimmune conditions may require intensive immunosuppressive therapy.
Source: Rheumatology International - December 28, 2022 Category: Rheumatology Source Type: research
Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab
AbstractThe authors present the case of a 76-year-old female patient with progressive decrease in proximal muscle strength, fatigue, dyspnea, diffuse hand edema and painful triphasic Raynaud ’s phenomenon. Anti-SRP and anti-SSA antibodies were detected, muscle biopsy revealed changes consistent with necrotizing myopathy and capillaroscopy had findings compatible with systemic sclerosis. High-resolution chest computed tomography revealed interstitial lung disease with a non-specific in terstitial pneumonia pattern. Lung function tests demonstrated a forced vital capacity 93% and a diffusing capacity for carbon monoxide of...
Source: Rheumatology International - June 18, 2022 Category: Rheumatology Source Type: research
Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
AbstractInflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases. All forms of myositis have progressive muscle weakness in common, with each subtype characterized by different autoantibody profiles, histological findings and extramuscular manifestations. Due to better understanding of the pathogenesis of the muscle inflammation in myositis, new molecular pathways for targeted therapy have been discovered. Current therapies aim at different components of ...
Source: Neurotherapeutics - April 8, 2022 Category: Neurology Source Type: research
Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data
CONCLUSIONS: HMGCR-associated IMNM is a rare subset of myositis. With systemic treatment, patients usually achieve partial or complete remission. Optimal treatment has not been established, but glucocorticoids, azathioprine, and methotrexate are generally effective with or without intravenous immunoglobulins.PMID:35225222
Source: Clinical and Experimental Rheumatology - February 28, 2022 Category: Rheumatology Authors: Jan-Gerd Rademacher Stefanie Glaubitz Sabrina Zechel Manuela Oettler Bj örn Tampe Jens Schmidt Peter Korsten Source Type: research
Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review
We describe the diverse clinical features in a series of 4 cases with anti-PM/Scl-75 and/or anti-PM/Scl-100 antibodies, including severe proximal muscle weakness, oesophageal dysfunction, respiratory weakness requiring mechanical ventilation, Raynaud ’s, calcinosis cutis, sclerodactyly and critical digital ischaemia. Despite the severity of striated and oesophageal muscle weakness, all patients responded very well to immune suppression, and calcinosis cutis in one case regressed substantially. We highlight the efficacy of Rituximab and intrave nous immunoglobulin therapy (IVIg) in these cases, enabling return to normal m...
Source: Rheumatology International - January 10, 2022 Category: Rheumatology Source Type: research
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report
Medicina (Kaunas). 2021 Dec 13;57(12):1358. doi: 10.3390/medicina57121358.ABSTRACTAnti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented with myalgia, Gottron's papules with ulceration, and dyspnea on exertion which became aggravated within weeks. Laboratory examination and electromyography confirmed myopathy changes, and a survey of myositis-specific antibodies was strongly positi...
Source: Medicina (Kaunas) - December 24, 2021 Category: Universities & Medical Training Authors: Tsai-Hung Yen Chih-Wei Tseng Kao-Lun Wang Pin-Kuei Fu Source Type: research
